CRIS

Curis, Inc.

11.12 USD
+0.30 (+2.77%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Curis, Inc. stock is down -25.92% since 30 days ago. The next earnings date is Aug 1, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 37.5% of the previous 23 May’s closed higher than April. 100% of analysts rate it a buy.

About Curis, Inc.

Curis, Inc. engages in the discovery and development of drug candidates for the treatment of human cancers in the United States. Its clinical stage drug candidates include Emavusertib, an oral small molecule drug candidate, which is in a Phase 1/2 clinical trial. CI-8993, a monoclonal antibody designed to antagonize the V-domain Ig suppressor of T cell activation.

  • Truist Securities
    Wed May 15, 14:21
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 15, 12:18
    buy
    confirm
  • Cantor Fitzgerald
    Wed May 15, 08:05
    buy
    confirm
  • HC Wainwright & Co.
    Wed May 8, 06:30
    buy
    confirm